VC-Run Dementia Discovery Fund Plays It Safe With First Investment
This article was originally published in Scrip
The Dementia Discovery Fund, launched in October 2015 to much fanfare in the UK, has made its first investment in an established US biotech company – not quite the move UK scientists were hoping for. The DDF is joining a syndicate of venture capital investors in a $29.5m series D financing in Alector LLC which is using antibodies to target neurodegeneration.
You may also be interested in...
Private Company Edition: Gossamer, Ascentage and Alector continued the trend of large venture capital rounds, recently raising $230m, $150m and $133m, respectively. Led by former Receptos executives, Gossamer has multiple clinical trials planned, but continues to keep details of its drug candidates under wraps.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.